Bio-Thera Solutions appears to be extending its streak of partnerships secured in 2024 into the new year, having announced a new deal with World Medicine that will license out Bio-Thera’s Stelara (ustekinumab) biosimilar BAT2206 to World Medicine for commercialization in its domestic Turkish market.
While the biosimilar will be manufactured in China, World Medicine will take care of the Stelara rival’s potential marketing authorization and subsequent commercialization. The originator drug Stelara was developed by...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?